Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation
==================================================================================================================================================================================================================================================================

* Viktoria Marquardt
* Johanna Theruvath
* David Pauck
* Daniel Picard
* Nan Qin
* Lena Blümel
* Mara Maue
* Jasmin Bartl
* Ulvi Ahmadov
* Maike Langini
* Frauke-Dorothee Meyer
* Allison Cole
* Joselyn Cruz-Cruz
* Claus M Graef
* Matthias Wölfl
* Till Milde
* Olaf Witt
* Anat Erdreich-Epstein
* Gabriel Leprivier
* Ulf Kahlert
* Anja Stefanski
* Kai Stühler
* Stephen T Keir
* Darell D Bigner
* Julia Hauer
* Thomas Beez
* Christiane B Knobbe-Thomsen
* Ute Fischer
* Jörg Felsberg
* Finn K Hansen
* Rajeev Vibhakar
* Sujatha Venkatraman
* Samuel H Cheshier
* Guido Reifenberger
* Arndt Borkhardt
* Thomas Kurz
* Marc Remke
* Siddhartha Mitra